LOGO
LOGO

Quick Facts

Lilly Lifts FY21 Adj. EPS, Revenue View Above Market - Quick Facts

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

While reporting weak earnings and higher revenues in its third quarter, drug maker Eli Lilly And Co. (LLY) on Tuesday trimmed its fiscal 2021 earnings view on a reported basis, while raised adjusted earnings and revenue forecast above market estimates.

In pre-market activity on the NYSE, Lilly shares were gaining around 2.02 percent to trade at $250.

For the year, the company now projects adjusted earnings of $7.95 to $8.05, higher than previous view of $7.80 to $8.00.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.